Skip to main content
      RT @RichardPAConway: Sattui @SattuiSEMD Treatment patterns in US in 26,102 PMR patients from RISE. Over 24 months <3%

      Richard Conway RichardPAConway

      3 years 10 months ago
      Sattui @SattuiSEMD Treatment patterns in US in 26,102 PMR patients from RISE. Over 24 months <3% used IL6i, 36% DMARD. DM and morbid obese more likely to use. Women, older, and using IL6i/DMARD more likely to have GC>1 year @RheumNow #ACR22 Abstr#1546 https://t.co/Imjsgyo49j https://t.co/8E5Rj5d7Pz
      RT @JulianSegan: Data from CorEvitas RA registry shows persistence for first-line monotherapy with etanercept, adalimuma

      Julian Segan JulianSegan

      3 years 10 months ago
      Data from CorEvitas RA registry shows persistence for first-line monotherapy with etanercept, adalimumab and JAKis no different at 12 months. 20-25% switching at 12-months. Clearly more to secondary failure than anti-drug antibodies. @RheumNow #ACR22 https://t.co/FeP0UAykUg https://t.co/ad9w9lI0Hu
      RT @RHEUMarampa: Nice study on referral strategies for #axSpA in pts w/ chronic LBP by Dr @Nellziade
      🔸MASTER strateg

      sheila RHEUMarampa

      3 years 10 months ago
      Nice study on referral strategies for #axSpA in pts w/ chronic LBP by Dr @Nellziade 🔸MASTER strategy-optimal reference strategy: IBP, ✅NSAID response, HLA-B27+ & +SpA family hx 🔸Clinical predictive factors: uveitis, IBP, Pso, enthesitis &🚹 #ACR22 @RheumNow ABST#1512 #ACRBest https://t.co/l6AleXX7Kt
      RT @doctorRBC: Biologics to treat gut microbiome dysbiosis??
      In axSpA pts treated with bDMARDs for one year, gut microbi

      Robert B Chao, MD doctorRBC

      3 years 10 months ago
      Biologics to treat gut microbiome dysbiosis?? In axSpA pts treated with bDMARDs for one year, gut microbiome resembled those of controls. Collinsella remained stable - possible biomarker? Abs#1162 @RheumNow #ACR22 #ACRBest https://t.co/vmQFJMpNPP
      RT @uptoTate: Abs 1153 at #ACR22 males may have a higher levels of Th17-associated transcription factors. Radiographic p

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      Abs 1153 at #ACR22 males may have a higher levels of Th17-associated transcription factors. Radiographic progression in men may be mediated by S100 proteins and prostaglandins. @RheumNow https://t.co/mWbsaB8kK8 https://t.co/IkTBZcaqa6
      We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR

      Dr. John Cush RheumNow

      3 years 10 months ago
      We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/iUY4azQQyD
      Much has been written about tapering medications in rheumatic diseases, often due to high costs of medications, a desire to avoid side effects and patient preference to take less medications (especially if they have side effects). This is countered by something we all know: medications not taken don’t work, and those that are frequently missed may not provide optimal outcomes for the majority of patients.
      RT @RichardPAConway: Raadsen et al. RA-specific CV risk specifically targets pre-existing atherosclerotic vessels. So if

      Richard Conway RichardPAConway

      3 years 10 months ago
      Raadsen et al. RA-specific CV risk specifically targets pre-existing atherosclerotic vessels. So if no baseline CVD, traditional risk factors are main driver rather than RA. Risk without prevalent CVD (HR 1.16 95%CI 0.88 –1.53) @RheumNow #ACR22 Abstr#1408 https://t.co/1Y6WeEFmim https://t.co/qG3RMNnbqt
      RT @RichardPAConway: Michailidou et al. PMR has increased neutrophil activation and NET formation. Elevated calprotectin

      Richard Conway RichardPAConway

      3 years 10 months ago
      Michailidou et al. PMR has increased neutrophil activation and NET formation. Elevated calprotectin. Immune complexes assoc neutrophil activation. Neutrophil activation inhibited by FcγRIIA blockade @RheumNow #ACR22 Abstr#1545 https://t.co/EAqZ3byMoP https://t.co/T2PmIExSKj
      RT @EBRheum: Another poster from my research group!

      Investigated recommendations in ACR/EULAR guidelines

      &lt;1/6th in

      Mike Putman EBRheum

      3 years 10 months ago
      Another poster from my research group! Investigated recommendations in ACR/EULAR guidelines <1/6th informed by head 2 head RCT We need more comparative effectivness research! #ACR22 @RheumNow #1284 https://t.co/HQoeKj0cxy
      RT @RichardPAConway: Moura et al. 22 case series of VEXAS. Lung involvement common, Symptoms in 95%. HRCT abnormal 73%.

      Richard Conway RichardPAConway

      3 years 10 months ago
      Moura et al. 22 case series of VEXAS. Lung involvement common, Symptoms in 95%. HRCT abnormal 73%. PFTs abnormal 20%. Changes non specific inflammatory parenchymal, steroid responsive. @RheumNow #ACR22 Abstr#1569 https://t.co/E6vUnvxSdQ https://t.co/l4aEmpy8OX
      RT @RichardPAConway: Fukui et al. Association different alcoholic drinks and urate in Japan. Patients always ask about t

      Richard Conway RichardPAConway

      3 years 10 months ago
      Fukui et al. Association different alcoholic drinks and urate in Japan. Patients always ask about this. We should drink more sake it seems! @RheumNow #ACR22 Abstr#1206 https://t.co/En5pSMUNp7 https://t.co/c67r9fsHJT
      ×